Skip to main content
. 2021 Jun 23;80(11):1419–1428. doi: 10.1136/annrheumdis-2021-220263

Figure 3.

Figure 3

Disease outcomes at month 6 (observed percentages). Observed percentages (intention-to-treat analysis set) including non-responder imputation. *cDAPSA remission ≤4. †Including remission; cDAPSA ≤13. ‡Including VLDA. cDAPSA, clinical Disease Activity Index for Psoriatic Arthritis; LDA, low disease activity; MDA, minimal disease activity; PS, propensity score; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab; VLDA, very low disease activity.